SUNOVION PHARMACEUTICALS INC

1455 Pennsylvania Ave NW, Washington, District of Columbia, United States

Clinical Trials

102

88 active

Approvals

Total approvals

Agencies

Regulatory bodies

Founded

N/A

Overview

Trial Phase Distribution

Phase

Trials

Phase 1

52.9%

Phase 3

9.8%

Not Applicable

2.9%

Trial Status Distribution

Active, not recruiting

86.3%

Completed

7.8%

Recruiting

1.0%

Unknown

2.0%

Clinical Trials

Trials sponsored by this organization (102)

An extension study to evaluate the long term safety, tolerability and effectiveness of SEP-4199 CR in patients with major depressive episodes associated with Bipolar I disorder.

Phase 1

Active, not recruiting

interventional

Jun 2023355 participants

Research study to evaluate the effectiveness of SEP-4199 CR in patients with major depressive episodes associated with Bipolar I Disorder.

Phase 1

Active, not recruiting

interventional

Jun 2023522 participants

A Clinical Study that will measure how well SEP-363856 works and how safe it is in adults with Generalized Anxiety Disorder

Phase 1

Recruiting

interventional

Apr 2023434 participants

A study to evaluate the long-term safety and tolerability of SEP-363856 in subjects with schizophrenia.

Phase 1

Active, not recruiting

interventional

Nov 2022612 participants

Research study to evaluate the effectiveness of SEP-4199 CR in patients with major depressive episodes associated with Bipolar I Disorder.

Phase 1

Active, not recruiting

Sep 2022522 participants

An extension study to evaluate the long term safety, tolerability and effectiveness of SEP-4199 CR in patients with major depressive episodes associated with Bipolar I disorder.

Phase 1

Active, not recruiting

Sep 2022355 participants

A study to evaluate the long-term safety and tolerability of SEP-363856 compared with an approved medicine in subjects with schizophrenia.

Phase 1

Active, not recruiting

Mar 2022300 participants

Research study to evaluate the effectiveness of SEP-4199 CR in patients with major depressive episodes associated with Bipolar I Disorder.

Phase 1

Active, not recruiting

Dec 2021522 participants

Page 1 of 13

Approvals

Approvals by Agency

NMPA

National Medical Products Administration

Approvals

Recent Approvals

Lurasidone Hydrochloride Tablets

NMPA

2019-03-08

Lurasidone Hydrochloride Tablets

NMPA

2019-03-06

Lurasidone Hydrochloride Tablets

NMPA

2019-01-24

News

No news articles found

Back to Organizations